BTG2, a p53-inducible antiproliferative gene, is stimulated in breast cancer cells by activation of nuclear factor kappa B (NF-jB). In rat mammary glands, BTG2 is expressed in epithelial cells and levels decreased during pregnancy and lactation but recovered during involution. Estrogen and progestin suppress BTG2 expression, suggesting that these steroids, which stimulate proliferation and lobuloalveolar development of mammary epithelial cells, may downregulate BTG2 in the mammary gland during pregnancy. Consistent with the report that BTG2 inhibits cyclin D1 expression, suppression of BTG2 mRNA in the mammary gland during gestation, and by estrogen and progestin, correlated with stimulation of cyclin D1. Ectopic expression of BTG2 inhibited breast cancer cell growth by arresting cells in the G1 phase, an effect reversed by cyclin D1. BTG2 expression was very low or undetectable in human breast cancer cell lines compared with nontumorigenic mammary epithelial cells, and nuclear expression of BTG2 was absent in 65% of human breast tumors compared with adjacent matched normal glands. Spontaneous mammary tumors arising in a mouse model with targeted expression of the early region of the SV40 large tumor Ag demonstrated loss of BTG2 protein very early during the tumorigenic process. Thus deregulation of BTG2 may be an important step in the development of mammary tumors.
Introduction
BTG2 was originally identified as an immediate early gene stimulated by the nerve growth factor (NGF) in the rat PC12 cell line during neuronal differentiation (Bradbury et al., 1991) , and in mouse 3T3 cell line by the tumor promoter tetradecanoyl phorbol acetate (Fletcher et al., 1991) . The rat and mouse homologs of BTG2 are designated TIS21 and Pc3, respectively (Fletcher et al., 1991) . BTG2 is expressed predominantly in the epithelium of many tissues (Melamed et al., 2002) and can be regulated in response to DNA damage induced by UV, ionizing radiations and adriamycin, and by NGF, interleukin-6, 12-O-tetradecanoylphorbol-13-acetate, epidermal growth factor (EGF), serum and cAMP (Matsuda et al., 2001; Tirone, 2001 ). The expression of BTG2 is inducible by p53 (Rouault et al., 1996) , and the presence of binding sites for nuclear factor kappa B (NF-kB), AP1 and GATA1 in the promoter of BTG2 (Duriez et al., 2002) suggests that it may also be responsive to stimuli that can activate transcription factors other than p53.
There is a strong correlation between BTG2 expression and negative regulation of growth: BTG2 is expressed during the G0/G1 transition and levels decline as cells enter the cell cycle (Rouault et al., 1996; Iacopetti et al., 1999) . Stable expression of BTG2 in cells impairs G1 to S progression (Montagnoli et al., 1996; Lim et al., 1998a; Guardavaccaro et al., 2000) . Conversely, BTG2-deleted cells continue to proliferate in response to DNA damage in comparison with control cells, which growth arrest (Rouault et al., 1996) . Furthermore, the detection of BTG2 in tumors was associated with decreased aggressiveness (Cmarik et al., 1994) . Recently, Kuo et al. (2003) demonstrated that BTG2 mRNA and other family members including BTG1 and BTG3 were strongly induced by the tumor suppressor p19
Arf (p14 in humans) in NIH3T3 cells conditionally expressing the P19 Arf transgene1. BTG2 prevents proliferation through Rb-dependent (Guardavaccaro et al., 2000) and -independent (Lim et al., 1998a) mechanisms. It represses the transcription of cyclin D1, an effect that lowers the kinase activity of the CDK4/cyclin D1 complex leading to hypophosphorylation of Rb (Guardavaccaro et al., 2000) . Furthermore, its ability to physically interact with CDK1 and CDK4 modifies the activity of CDK4/cyclin E complex, which is critical for G1 to S transition in Rbnegative cells (Lim et al., 1998a) . The antiproliferative function of BTG2 can also be explained by its interaction with PMRT1 (protein arginine methyltransferase of type I) (Lin et al., 1996; Lim et al., 1998b) , which through methylation of proteins may be involved in the transduction of antiproliferative and differentiation signals, and Caf1 (a homolog of the yeast Caf1/ Pop2, a component of the CCR4 transcription complex), a regulator of a number of genes involved in cell cycle regulation and progression (Rouault et al., 1998) . BTG2 also associates with HoxB9 and enhanced HoxB9-dependent transcription of antiproliferative genes such as NCAM (Prevot et al., 2000; Sakaguchi et al., 2001) .
The BTG2 gene localizes to chromosomal locus 1q32 (Duriez et al., 2002) , and loss of heterozygosity at 1q23-32 appears to be one of the lesions associated with development of breast cancer (Chen et al., 1989) . However, little is known about the role of BTG2 in mammary gland development and tumorigenesis, and so far no mutations in the BTG2 gene have been reported in breast cancer. In this paper, we demonstrate that activators of the NF-kB pathway such as the Mullerian inhibiting substance, a member of the transforming growth factor (TGF) b superfamily, and tumor necrosis factor-a (TNF-a) induce BTG2 expression in breast cancer cells. In the rat mammary gland, BTG2 expression dramatically declined during pregnancy, while cyclin D1, a gene reported to be suppressed by BTG2, was upregulated. Estrogen and progestin suppressed BTG2 mRNA in vitro, suggesting that BTG2 expression in the mammary gland may be regulated by these steroids, which are involved in growth and differentiation of the breast. Consistent with its antiproliferative activity, BTG2 suppressed breast cancer cell growth, and its expression was deregulated in mammary tumors. Thus BTG2 may be a negative regulator of mammary epithelial cell growth.
Results

Activation of NF-kB induces BTG2 expression in breast cancer cells
BTG2 was identified as a target gene induced by MIS in human breast cancer cells using an HG-U95Av2 oligonucleotide array. Northern blot analysis of RNA isolated from T47D cells confirmed the induction of BTG2 by MIS (Figure 1a) . Since we had previously demonstrated that MIS induces NF-kB DNA binding activity (Segev et al., , 2001 (Segev et al., , 2002 , and the BTG2 promoter is reported to have an NF-kB consensus DNA binding element (Duriez et al., 2002) , we tested whether stimulation of BTG2 by MIS was mediated through activation of the NF-kB pathway. As shown in Figure 1a , upregulation of BTG2 mRNA by MIS was mitigated by the expression of dominant-negative IkB-a, suggesting that activation of the NF-kB pathway was required for this process ( Figure 1a) . We had previously demonstrated that expression of dominant-negative IkB-a in T47D cells abrogates NF-kB DNA binding activity induced by MIS . TNF-a, a cytokine that robustly activates NF-kB signaling, also induced BTG2 expression in breast cancer cells through an NF-kB-dependent mechanism (Figure 1b ).
BTG2 expression in the mammary gland is suppressed during pregnancy
Since BTG2 expression is associated with regulation of growth and differentiation, we analysed the expression of BTG2 in the mammary gland during postnatal morphogenesis. During pregnancy, under the influence of luteal and placental sex steroids and other hormones, the epithelial cells undergo extensive proliferation resulting in a marked increase in ductal, lobular and acinar growth. At the completion of lobuloacinar growth, terminal differentiation of the secretory cells leads to synthesis and secretion of milk components. During weaning, the glandular epithelial cells of the mammary gland undergo extensive apoptosis, and the mammary gland returns to a histologic state similar to the resting state (Nandi, 1958) .
BTG2 mRNA was readily detectable in the mammary glands of virgin rats and expression was gradually downregulated in the rat mammary gland during pregnancy and there was no detectable BTG2 expression in the lactating glands but levels recovered during involution (Figure 2a) . Phosphorimaging of band intensities from three animals per time point demonstrated a 50% decline on gestational day 5 (G5) to 30% on G11 and to 15% on G20 compared to that in virgin animals (set at 100%; Figure 2b , n ¼ 3).
The localization of BTG2 protein in the mammary gland determined by immunohistochemical analysis was consistent with the results obtained by Northern analysis. As seen in Figure 2c , BTG2 protein expression was detectable in the nuclei of myoepithelial and luminal epithelial cells of the ducts and lobules of the mammary Figure 1 Activation of NF-kB induces BTG2. (a) T47D cells and T47D cells expressing the dominant-negative IkB-a transgene were treated with 35 nM MIS and total RNA (7.5 mg) was analysed by Northern blot. (b) T47D cells and those expressing dominantnegative IkB-a were treated with TNF-a for 2 h and total RNA (7.5 mg) was analysed for BTG2 expression. Hybridization to 18S is shown BTG2 expression in breast cancer H Kawakubo et al gland. While 100% of the nuclei of epithelial cells lining the ducts of virgin mammary glands were positive for BTG2 staining, the percentage of epithelial cell nuclei expressing the BTG2 protein gradually decreased during pregnancy with almost no expression during late pregnancy (G20) or in the lactating mammary gland. Expression recovered in the mammary glands of weaned animals.
Cyclin D1 expression overcomes BTG2-mediated inhibition of breast cancer cell growth Since BTG2 expression is associated with antiproliferative activity, we tested whether expression of BTG2 could inhibit breast cancer cell growth using colony inhibition assays. A human BTG2 cDNA expressing the protein (Figure 3a ) was cotransfected into MCF7 cells along with a plasmid encoding hygromycin resistance. The PCDNA vector (V) construct was transfected into cells as control. Cells were grown in the presence of hygromycin for 3 weeks and drug-resistant colonies were counted. Expression of BTG2 in cells resulted in about 70% reduction in drug-resistant colonies compared to vector-transfected cells (n ¼ 3; Figure 3b ).
To test whether inhibition of breast cancer cell growth by BTG2 was associated with cell cycle arrest, MCF7 cells were transfected with constructs encoding BTG2 along with a plasmid encoding the cell surface marker Figure 2 Regulation of BTG2 expression during postnatal morphogenesis of the mammary gland. (a) Total RNA (7.5 mg) isolated from mammary glands of 8-week-old virgin, pregnant (G: gestation; G5-G21), lactating (PD: postdelivery; PD0-PD10) and weaned (pups removed 2 days after lactation; PD3-PD10) rats (n ¼ 1 for each sample) was analysed for BTG2 expression by Northern blot. (b) Total RNA (7.5 mg) isolated from mammary glands of rats during indicated periods of development was analysed for BTG2 expression (n ¼ 3). To measure changes in BTG2 expression, band intensities were quantified using phosphorImager and iQMac data analysis software. (c) Immunohistochemical detection of BTG2 protein in the rat mammary gland. Paraffin-embedded mammary tissue sections from various stages of postnatal morphogenesis shown above were stained with an anti-BTG2 antibody (original magnification Â 125). The slides were counterstained with hematoxylin BTG2 expression in breast cancer H Kawakubo et al CD20 as described by van den Heuvel and Harlow (1993) . Analysis of CD-20-positive transfectants by fluorescence-activated cell sorter (FACS) analysis for DNA content demonstrated a 10-12% increase in the fraction of cells in the G1 phase of the cell cycle compared to cells transfected with the vector (Figure 3c ). Since the antiproliferative activity of BTG2 has been reported to result from its ability to inhibit cyclin D1 expression (Guardavaccaro et al., 2000) , we tested whether coexpression of cyclin D1 can overcome BTG2-mediated inhibition of growth. As seen previously, BTG2-transfected cultures had a lower number of colonies compared to vector-transfected controls, while expression of cyclin D1 alone resulted in a statistically significant increase in colony numbers. Coexpression of cyclin D1 and BTG2 counteracted the effect of the other (Figure 3d ).
In the mammary glands of rats, unlike BTG2, which gradually declines during pregnancy, cyclin D1 mRNA sharply increased at early gestation compared with that in virgin animals. Through late gestation, cyclin D1 mRNA was maintained at levels higher than that in virgin rats but declined at lactation. During the early days of involution, coincident with a strong induction of BTG2, cyclin D1 mRNA decreased further and was undetectable ( Figure 3e , upper panel). Immunohistochemical analyses of cyclin D1 protein in the mammary glands of rats were in agreement with the above results ( Figure 3e , middle panel). Since the expression of BTG2 and cyclin D1 in the mammary glands of rats demonstrated a striking negative correlation during early periods of gestation, we analysed their expression in a larger cohort of timed-pregnant female rats (n ¼ 3). The inverse correlation between BTG2 and cyclin D1 expression during early gestation ( Figure 3e , lower panel) was consistent with the finding that BTG2 can suppress cyclin D1 (Guardavaccaro et al., 2000) .
Moreover, estrogen and progesterone, important factors in stimulating breast growth during pregnancy, suppressed BTG2 and induced cyclin D1. In MCF7 cells, estrogen-mediated suppression of BTG2 correlated with induction of cyclin D1 expression (Figure 3f , left panel). Similarly, suppression of BTG2 expression in T47D breast cancer cells by the progestin R5020 was also associated with an increase in cyclin D1 (Figure 3f , right panel). TNF-a, an activator of the NF-kB pathway, also suppressed cyclin D1 expression in T47D cells (Figure 3g ).
BTG2 expression is aberrantly regulated in breast tumors
Since BTG2 expression in breast cancer cells inhibited growth, we wished to determine whether BTG2 expression would be deregulated in breast cancer. Analysis of BTG2 expression in human breast cancer cell lines demonstrated that compared to levels observed in 184A1 and MCF10A, two immortalized normal human mammary epithelial cell lines, expression was much lower in breast cancer cell lines and was almost undetectable in the estrogen receptor-negative MDA-MB-468, MDA-MB-435 and MDA-MB-231 breast cancer cells ( Figure 4A ).
We then analysed the expression of BTG2 in human breast cancer by immunohistochemical analysis of breast tissue resected from 23 breast cancer patients. These included 14 poorly differentiated (histologic grade 3), five moderately differentiated (histologic grade 2) and four well-differentiated (histologic grade 1) ductal adenocarcinomas. The specificity of the antibody to detect human BTG2 protein by immunohistochemistry was confirmed by preincubating the antibody with COS cells expressing a transiently transfected human BTG2 expression construct. Normal human breast tissue was analysed by immunohistochemistry following incubation with the anti-rabbit BTG2 antibody, anti-BTG2 antibody preincubated with vector-transfected COS protein lysate or anti-BTG2 antibody preincubated with BTG2-transfected COS protein lysates. As seen in Figure 4B , the anti-BTG2 antibody and the anti-BTG2 antibody preincubated with vector-transfected COS cell protein detected the BTG2 protein in the epithelial and myoepithelial cells of normal ducts and lobules. However, preincubation of the antibody with BTG2-expressing COS cell protein extracts abolished staining. Staining was also absent when the tissue was incubated with affinity-purified rabbit immunoglobulins (data not shown).
In 15 of 23 breast cancer samples analysed, nuclear expression of BTG2 was absent in the tumor but very strong BTG2 staining was detectable in the nuclei of the epithelium of ducts and lobules in the surrounding normal tissue. These consisted of 11 tumors of histologic grade 3, three turmors of histologic grade 2 and one tumor of histologic grade 1. In the remaining eight cases, BTG2 expression was observed in the nuclei of both the uninvolved ducts and in the tumor, with no discernible difference in levels ( Figure 4C ).
BTG2 expression is suppressed during mammary gland tumorigenesis in mice
In order to determine changes in BTG2 expression during tumor progression, we studied BTG2 expression in mammary tumors, which arise spontaneously in transgenic mice, that express the early region of the SV40 large tumor Ag under the regulation of the rat prostatic steroid binding protein promoter (Green et al., 2000) . In this mouse mammary carcinoma model, almost all transgenic female mice develop atypical ductal hyperplasia by 8 weeks, nodular atypical hyperplasia by 12 weeks and invasive carcinomas by 16-20 weeks (Green et al., 2000) . This provided us with a model to study the expression of BTG2 during mammary tumor progression.
BTG2 protein expression during mammary gland tumorigenesis in this mouse model was analysed by immunohistochemistry. In nontransgenic mice, BTG2 protein localized predominantly to the nucleus of epithelial cells in normal ducts and lobules of the mammary gland (Figure 5a ). In the transgenic mice, epithelial cells expressing BTG2 were interspersed with BTG2 expression in breast cancer H Kawakubo et al nonexpressing cells in ducts exhibiting atypical hyperplasia (Figure 5b and d) . Thus loss of BTG2 expression may represent an early event in neoplastic transformation of the mammary gland. Furthermore, BTG2 was consistently absent in small nodules of tumors observed in 12-week-old animals but present in the epithelial cell nuclei of nontumor tissue (Figure 5c and d) . BTG2 expression was also absent in advanced mammary adenocarcinomas of older animals but was expressed in the adjacent nontumor tissue (Figure 5e-h ).
Discussion
The decline in BTG2 expression in the mammary gland during gestation, deregulation of its expression in mammary tumors and inhibition of breast cancer cell growth by ectopic expression of BTG2 suggest that BTG2 may have a tumor suppressor function in mammary epithelial cells. BTG2 was originally described as a p53-inducible gene and contains six consensus p53 DNA binding sites in the 5 0 flanking region and the first intron. The induction of BTG2 in T47D cells, which contain a transactivation-deficient p53 allele mutated at codon 194 (Nigro et al., 1989; Wosikowski et al., 1995) , suggests that BTG2 expression may be regulated through p53-independent mechanisms as well. The presence of an NF-kB site in the promoter region of BTG2 (Duriez et al., 2002) renders it responsive to signals such as MIS and TNF-a, which robustly induce NF-kB. The partial abrogation of BTG2 induction by MIS in T47D cells expressing dominant-negative IkB-a suggests that other transcription factors besides NF-kB may also be involved in MIS-mediated induction of BTG2. In fact characterization of the BTG2 promoter revealed the presence of putative DNA binding sites for many transcription factors including AP1, GATA1 and SP1 (Duriez et al., 2002) . The kinetics of BTG2 induction is stimulus dependent. EGF and NGF transiently induce BTG2 in PC12 cells by 1 h (Bradbury et al., 1991) . However, in MCF7 cells maximal induction of BTG2 by g-irradiation, adriamycin and UV occurred around 3-6 h and persisted for longer periods of time (Cortes et al., 2000) . MIS and TNF-a induce BTG2 mRNA in T47D cells after 2 h of treatment and the levels are maintained above basal for up to 24 h.
The dynamic expression pattern of BTG2 during postnatal morphogenesis of the mammary glands suggests that it may play an important role in regulating growth and differentiation processes in this tissue. The mammary gland is a target tissue for estrogens, depending on it for hormonal stimulation of epithelial cell proliferation. During pregnancy, circulating estrogen is high and, by means of a complex hormonal interplay with progesterone, prolactin and growth hormone, stimulates mammary epithelial cells to proliferate and undergo lobuloalveolar development. The ability of estrogen and progestin to suppress BTG2 expression suggests that these steroids may be involved in downregulating BTG2 mRNA in the mammary gland during pregnancy.
BTG2 and cyclin D1 expressions demonstrate an inverse correlation in the rat mammary gland during early gestation, and estrogen and progestin treatment of breast cancer cells suppressed BTG2 expression with an associated increase in cyclin D1. These observations are consistent with the report that BTG2 downregulates cyclin D1 expression (Guardavaccaro et al., 2000) .
Cyclin D1 has been identified as a target gene induced following activation of the NF-kB pathway (Horwitz (4) 5 mg of cyclin D1. Total amount of DNA transfected was equalized with PCDNA vector. Colonies, which grew in medium containing 100 mg/ml hygromycin for 3 weeks, were stained with crystal violet. Colonies in plates transfected with vector were set at 100%. (e) Cyclin D1 and BTG2 expressions demonstrate an inverse correlation in the mammary glands of rats. Upper panel: The blot containing total RNA isolated from the mammary glands of rats described in Figure 2a and probed for BTG2 was reanalysed for cyclin D1 expression. Hybridization to 18S is shown in Figure 2a . Middle panel: Immunohistochemical detection of cyclin D1 protein in the rat mammary gland. Paraffin-embedded mammary tissue sections from various stages of postnatal morphogenesis shown above were stained with an anti-cyclin D1 antibody (original magnification Â 125). The slides were counterstained with hematoxylin. Lower panel: Inverse correlation between cyclin D1 and BTG2 expression in the mammary glands during early gestation. Total RNA isolated from the mammary glands of rats (n ¼ 3) was analysed for BTG2 and cyclin D1 expression by Northern blot. Positions of cyclin D1 and BTG2 are shown. Hybridization to 18S is shown to control for loading. (f) Suppression of BTG2 expression in breast cancer cells by estrogen and progestin treatment is associated with stimulation of cyclin D1. Left panel: MCF7 cells grown in estrogen-deprived medium for 4 days were treated with 1 nM estrogen for 2 and 4 h. Total RNA (7.5 mg) was analysed for BTG2 and cyclin D1 expression. Right panel: T47D cells grown in charcoal-stripped serum for 4 days were treated with 10 nM of the progestin R5020 for 2 and 4 h. Total RNA was analysed for BTG2 and cyclin D1 expression. Quantification of transcript levels by phosphorimaging is shown for both blots. Expression in the untreated sample was set at 1. Hybridization to 18S is shown to control for loading. (g) T47D cells were treated with 1 ng/ml TNF-a for 2, 6 and 24 h and total RNA was analysed for BTG2 and cyclin D1 expression BTG2 expression in breast cancer H Kawakubo et al et al., 1997; Guttridge et al., 1999; Hinz et al., 1999; Whitehead et al., 1999) . However, our results demonstrate that TNF-a, a potent activator of the NF-kB pathway, induced BTG2 and suppressed cyclin D1 in T47D cells. These results are consistent with the observation that NF-kB activation by TNF-a was not sufficient to induce cyclin D1 (Hinz et al., 1999) . Modulation of cyclin D1 by NF-kB demonstrates a complex regulation that is dependent on the context of cell and stimulus, and Rel/NF-kB dimers with different activities (Kaltschmidt et al., 1999; Nakamura et al., 2002; Rocha et al., 2003) . In HeLa cells, suppression of NF-kB activity with the dominant-negative IkB-a impaired proliferation but did not result in any change in cyclin D1 levels (Kaltschmidt et al., 1999) . Induction of p53 suppresses cyclin D1 by regulating Bcl-3 levels and enhancing the association of p52 with HDAC1. Since BTG2 is target of p53, it is interesting to speculate that suppression of cyclin D1 by BTG2 may involve a similar mechanism (Rocha et al., 2003) .
Cyclin D1 is overexpressed in 50% of mammary carcinomas (Gillett et al., 1996) , and overexpression of cyclin Dl in mammary glands results in abnormal mammary cell proliferation including the development of mammary adenocarcinomas (Wang et al., 1994) suggesting that increased levels of cyclin D1 may contribute to neoplastic transformation of the breast. Coexpression of cyclin D1 has been shown to reverse BTG2-mediated inhibition of cell cycle progression (Guardavaccaro et al., 2000) . Colony inhibition assays to determine the effects of cyclin D1 and BTG2 on breast cancer cell growth revealed that cyclin D1 expression in MCF7 cells significantly enhanced growth while ectopic expression of BTG2 suppressed growth. A combination of BTG2 and cyclin D1 counteracted the growth regulatory effects of each other. Thus BTG2 may be one of the factors involved in regulating the expression and function of cyclin D1 in the breast.
Several lines of evidence suggest an important role for BTG2 in the suppression of carcinogenesis. Expression analysis of BTG2 during prostate carcinogenesis demonstrated that reduction or loss of BTG2 expression was coincident with malignant progression. In highgrade prostatic intraepithelial neoplasia, which are considered to be probable precursor lesions for a subset of prostate cancers, BTG2 expression was either absent or limited to weak cytoplasmic expression suggesting that loss of BTG2 expression may be an early event in prostate cancer progression. BTG2 expression was also undetectable in higher grade tumors and in bone metastases (Ficazzola et al., 2001) . Furthermore, thymic 
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H Kawakubo et al carcinoma tissues derived from SV40T-Ag harboring transgenic mice did not express BTG2 (Lim et al., 1995) . Recently, Struckmann et al. (2004) demonstrated that BTG2 expression was suppressed in clear cell renal carcinoma suggesting that downregulation of BTG2 may be an important step in renal cancer development.
Our results demonstrate that nuclear BTG2 expression was absent in 65% of human breast tumors compared with surrounding matched normal tissue. Moreover, analysis of BTG2 expression in spontaneous mammary tumors that arise in transgenic mice expressing the early region of the SV40 large tumor Ag (Green et al., 2000) suggests suppression on BTG2 may be an early event during neoplastic progression of the mammary gland. Interestingly, mammary tumors arising in these mice are reported to have higher levels of cyclin D1 and cyclin E compared to normal mouse mammary glands (Desai et al., 2002) . Thus deregulation of BTG2 expression may be a crucial point in the pathogenesis of some types of cancer.
The dynamic pattern of BTG2 expression in the mammary gland during pregnancy and its loss early in the tumorigenic process suggests that BTG2 may play an important role in transformation and/or differentiation of the mammary gland. The interaction of BTG2 with the cell cycle machinery and its physical association with several growth regulatory proteins may present it to be an ideal candidate for inactivation during the tumorigenic process. Animal models in which BTG2 expression is targeted to the mammary gland may provide further insight into the role of BTG2 in the tumorigenic process in the breast. 
Materials and methods
Cell culture
Human breast cancer cell lines T47D, MCF7, MDA-MB-231, MDA-MB-435 and MDA-MB-468 and A549 were grown in Dulbecco's modified medium supplemented with 10% female fetal bovine serum, glutamine and penicillin/streptomycin. The nontumorigenic MCF10A cells (ATCC) were grown in mammary epithelial growth medium (MEGM, Clonetics) supplemented with 100 ng/ml cholera toxin (Calbiochem) and the 184A1 cells (a kind gift from Dr Martha Stampfer) were grown in MEGM supplemented with transferrin and isoproterenol. Human recombinant MIS (rhMIS) was collected from growth media of Chinese hamster ovary cells transfected with the human MIS gene and purified as described (Ragin et al., 1992) . T47D cells stably expressing IkB-a-DN were generated as described by Hoshiya et al. (2003) . TNF-a was purchased from Promega.
Western blot analysis
The characterization of the rabbit anti-BTG2 antibody has been described (Ficazzola et al., 2001) . Expression of BTG2 protein in COS and MCF7 cells was analysed by Western blot using a rabbit anti-BTG2 antibody according to the protocol described .
Animals
All animals were cared for and experiments were performed in this facility under AAALAS approved guidelines using protocols approved by the Institutional Review BoardInstitutional Animal Care and Use Committee of the Massachusetts General Hospital. BTG2 expression analysis in the rat mammary gland during postnatal morphogenesis was carried out using Sprague-Dawley rats. Mammary glands were harvested bilaterally from each animal for RNA isolation and immunohistochemical analysis.
The transgenic mouse model for spontaneous mammary carcinoma resulting from tissue-specific targeted expression of the early region of the SV40 large tumor Ag using the promoter of the rat prostatic steroid binding protein has been described (Green et al., 2000) . After establishing a mouse colony, mammary glands were resected from 6-, 12-, 18-and 24-week-old animals. Tissue was fixed in 4% paraformaldehyde and embedded in paraffin for immunostaining.
RNA analysis
The EST clones to detect the expression of human and mouse BTG2 and the rat cyclin D1 were purchased from Incyte Genomics Inc. The human cyclin D1 expression construct was a kind gift from Dr Phil Hinds. For Northern blot analysis, equal amounts of RNA were separated on a formaldehyde gel, transferred to Hybond-N membrane (Amersham) and probed with either human/mouse BTG2 or human/rat cyclin D1.
Immunohistochemical analysis
A total of 23 cases of human breast carcinoma with adjacent uninvolved breast parenchyma were selected from the files of the Massachusetts General Hospital (MGH) Pathology Department according to protocols approved by the Human Research Committee at MGH.
To establish the specificity of the BTG2 antibody, the antibody was preincubated with COS cell protein lysates derived from either vector-or BTG2-transfected cells. Briefly, 6 mg of either PCDNA vector or PCDNA-BTG2 was transiently transfected into COS cells using FUGENE-6 and proteins were extracted with RIPA buffer 48 h after transfection. The rabbit anti-BTG2 antibody was preincubated with either the vector-or BTG2-expressing COS protein lysate for 1 h at room temperature. Normal human breast tissue sections were analysed by immunohistochemistry (see below) using the anti-BTG2 antibody, BTG2 antibody preincubated with vector-transfected COS cell proteins or BTG2 antibody preincubated with BTG2-transfected COS cell proteins.
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded 5 mm tissue sections according to standard procedures. Deparaffinized tissue sections were treated with 3% hydrogen peroxide for 10 min to inhibit endogenous peroxidase. After the sections had been microwaved in a 10 mM citrate buffer solution at 100 W for 25 min, they were incubated with 10% normal goat serum for 30 min to block any nonspecific protein binding. For BTG2 detection, sections were incubated with rabbit antibodies against human BTG2 at room temperature overnight at a final antibody concentration of 1 mg/ml diluted in blocking serum solution. After incubation with biotinylated link antibody and peroxidase-labeled streptavidin, the staining was developed by reaction with diaminobenzidine (DAB) or Nova Red for 5 min. Detection chemistries were all purchased from Vector Laboratories (Burlingame, CA, USA), and used according to the manufacturer's instructions. The sections were lightly counterstained with hematoxylin and then mounted with a coverslip. Sections were stained with similar concentrations of affinity-purified rabbit immunoglobulins as controls. Immunohistochemical stains were evaluated semiquantitatively and ranged from negative to positive nuclear expression.
The mouse monoclonal anti-human cyclin D1 antibody (NCL-CYCLIN D1-GM) was purchased from Novocastra Laboratories. The protocol used for immunohistochemical detection of cyclin D1 was essentially similar to that described above, except for the following steps. The sections were treated with 0.3% hydrogen peroxide to inhibit endogenous peroxide and incubated with 40 mg/ml of primary antibody for 1 h at 371C.
Growth inhibition assays
To measure the ability of BTG2 to inhibit cellular proliferation, MCF7 cells were transfected with empty PCDNA vector, BTG2 and cyclin D1 expression constructs along with a hygromycin resistance plasmid. Cells were grown in the hygromycin-containing medium for 2-3 weeks, stained with crystal violet and drug-resistant colonies were counted.
Cell cycle analysis
To analyse the effect of BTG2 on cell cycle progression, MCF7 cells in logarithmic growth phase were transiently transfected with either vector or BTG2 expression construct along with a plasmid encoding the cell surface marker CD20 as described (van den Heuvel and Harlow, 1993) . Cells were fixed for 24 h after transfection and stained for CD20 expression and for DNA content using propidium iodide. The cell cycle distribution of CD20-positive cells was determined by FACS analysis.
